CAMBRIDGE, Mass. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today reported financial results for the third quarter ended September 30, 2018 and provided a business update.
Solid Biosciences is a life science company focused on solving Duchenne muscular dystrophy. We aim to be the center of excellence across the entire disease spectrum, serving as a catalyst to bring together those with expertise in science, technology, disease management and care. Disease-focused and founded by a family directly impacted by Duchenne muscular dystrophy, our mandate is simple yet comprehensive – attack the roots of the disease and improve daily life for patients.